Skip to content
Peptide research

IGF-1 LR3

Also known as Long R3 IGF-1
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

A long-acting analog of IGF-1 marketed for muscle growth, fat loss, and recovery. Extended activity is documented, but growth and repair claims rest mainly on animal and mechanism studies; human evidence is minimal and safety data are largely absent. Hypoglycemia is common and sometimes fatal with insulin, and its growth-signaling effects raise a real, unresolved cancer concern. Not an approved drug in the US; supply consists of unregulated products sold online.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

IGF-1 LR3 is an engineered, 83-amino-acid IGF-1 analogue with a position-3 substitution and a 13-amino-acid extension. It binds IGF carrier proteins weakly. Potency depends on the assay; a 20–30-hour human half-life is unestablished. It has no FDA approval for human use.

How it works in the body

A modified IGF-1 with a glutamate-to-arginine substitution at position 3 and a 13-amino-acid extension. These changes reduce IGFBP binding; animal studies found faster blood clearance. It activates IGF-1 receptors to drive muscle protein synthesis, cell proliferation, and anti-apoptotic signaling.

Research overview

IGF-1 LR3 has been studied primarily in animal models and cell culture systems. No human clinical trials have been conducted specifically on this compound — human safety and efficacy data are extrapolated from studies of native IGF-1 (which is FDA-approved as mecasermin/Increlex for primary IGF-1 deficiency). Animal studies show that LR3 IGF-1 stimulates growth of multiple organs including the adrenal glands, gut, kidneys, and spleen, and promotes cell proliferation through key growth pathways. Recent research has explored intranasal delivery for Alzheimer's disease, showing favorable changes in amyloid plaques but no cognitive improvement. The compound is widely used as a laboratory reagent to keep cells alive and growing. Its potential for sports doping has driven significant research into detection methods, though no internationally recognized test for detecting its misuse currently exists.

Who researches IGF-1 LR3?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

Important considerations for

  • Those with Active cancer

    Absolute

    Extended-half-life IGF-1 directly promotes tumor cell proliferation and inhibits apoptosis.

  • Those with Diabetic retinopathy

    High

    Prolonged IGF-1 receptor activation worsens retinal neovascularization.

  • Those with Hypoglycemia-prone individuals

    High

    IGF-1 LR3 can cause severe hypoglycemia. 20-30 hour half-life means prolonged glucose-lowering effect.

  • Those with Organ enlargement risk (high-dose/prolonged use)

    Moderate

    Chronic supraphysiological IGF-1 can cause visceral organ enlargement (heart, kidneys, intestines).

Safety & interactions

Do not use if

  • Active cancer

    Absolute

    Extended-half-life IGF-1 directly promotes tumor cell proliferation and inhibits apoptosis.

  • Diabetic retinopathy

    High

    Prolonged IGF-1 receptor activation worsens retinal neovascularization.

  • Hypoglycemia-prone individuals

    High

    IGF-1 LR3 can cause severe hypoglycemia. The duration of glucose lowering in humans is unestablished.

  • Organ enlargement risk (high-dose/prolonged use)

    Moderate

    Chronic supraphysiological IGF-1 can cause visceral organ enlargement (heart, kidneys, intestines).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(10)

Rated by level of concern

  • Hypoglycemia (low blood sugar) - most common acute side effect, reported at virtually all dose levels; risk dramatically increased when combined with insulin, with fatalities reported

    High

    PMID 9483305 (LR3 lowered plasma glucose in calves); Increlex FDA label, Warnings 5.1 and Adverse Reactions 6.1.

  • Potential cancer acceleration - promotes cell growth and inhibits apoptosis; one observational study linked higher endogenous IGF-1 to increased all-cancer mortality in older men; it did not measure LR3 risk

    Moderate

    PMID 15110491 (Renehan, Lancet 2004; ORs 1.49 prostate / 1.65 premenopausal breast, incidence); PMID 23658701 (LR3 anti-apoptotic signaling in prostate epithelium); Increlex FDA label Contraindications 4 and Warnings 5.7

  • Insulin resistance with chronic use - frequent use can push the body toward insulin resistance, creating long-term metabolic complications

    Theoretical

    PMID 9483305 (acute effect is opposite in direction); no primary study supporting the insulin-resistance claim has been identified

  • Fluid retention and edema - water retention is a commonly reported side effect

    Low

    Increlex FDA label Adverse Reactions 6.1 (label-sourced; the >=5% threshold is unconfirmed); mechanism from IGF-1 renal sodium handling

  • Joint pain and stiffness - musculoskeletal discomfort is frequently reported

    Moderate

    Increlex FDA label Adverse Reactions 6.1; Warnings 5.5, 5.6 (label-sourced)

  • Acromegaly-like changes with prolonged use - potential for bone and soft tissue overgrowth with long-term exposure

    Low

    PMID 7561636 (organ growth with LR3); PMID 11999215; Increlex FDA label Warnings 5.4 and Adverse Reactions 6.1

  • Endocrine disruption - suppression of natural growth hormone and IGF-1 production via negative feedback

    Moderate

    PMID 9488001 (23% mean GH reduction, 60% reduction in GH peak AUC, reduced IGFBP-3 and endogenous IGF-I in pigs); PMID 7561636; PMID 9252489 (LR3 lowered native IGF-I and GH in calves)

  • No human clinical trial safety data - all safety information is extrapolated from animal studies and native IGF-1 human data

    High

    PMID 20675162 (black-market analysis, Growth Horm IGF Res 2010); PMID 33587816 (Drug Test Anal 2021, detection windows established in laboratory animals); no interventional human trial of LR3 identified

  • Unregulated product quality - unregulated products sold online are not made to pharmaceutical manufacturing standards (GMP); contamination and dosing inaccuracies are possible

    High

    PMID 20675162 (His-tagged Long-R3-IGF-I found in a black-market vial); PMID 33587816 (oxidized/low-quality forms in black market products)

  • Headaches and nausea - commonly reported at various dose levels

    Low

    Increlex FDA label Adverse Reactions 6.1; Warnings 5.3 (intracranial hypertension) - label-sourced

Interaction summary(8)

Rated by direction with this peptide

  • Insulin

    CautionHigh

    Directly additive hypoglycemic effect - IGF-1 analogues lower glucose through IGF-1R and insulin-receptor cross-activation, and LR3's IGFBP evasion makes the effect larger and longer, so concurrent insulin can produce severe hypoglycemia, seizures or loss of consciousness.

    Increlex (mecasermin) FDA label, Warnings 5.1 and Adverse Reactions 6.1; PMID 9483305 (parenteral Long-R3-IGF-I reduced plasma glucose and insulin in calves - direct evidence the analogue itself is glucose-lowering)

  • Sulfonylureas, meglitinides and other insulin secretagogues / oral antidiabetic agents

    CautionHigh

    Same additive glucose-lowering mechanism as insulin; antidiabetic drug doses generally require downward adjustment when an IGF-1 agonist is added, and unadjusted regimens risk symptomatic hypoglycemia.

    Increlex FDA label, Warnings 5.1 (glucose monitoring and adjustment of concomitant hypoglycemic agents). Class-level extrapolation - no LR3-specific interaction study exists; severity kept High because the potential consequence (severe hypoglycemia) is severe, not because the LR3 evidence is strong.

  • Active malignancy or history of malignancy (and concurrent oncologic therapy)

    CautionHigh

    IGF-1R signaling is proliferative and anti-apoptotic, and rhIGF-1 is formally contraindicated in patients with malignancy or a history of malignancy after cases of malignant neoplasia in treated patients.

    Increlex FDA label, Contraindications 4 and Warnings 5.7; PMID 23658701 (LR3-IGF-I drives prostate epithelial growth via survivin/TGF-beta/mTORC1)

  • Growth hormone (somatropin) and GH secretagogues

    CautionModerate

    Using a GH agent with an IGF-1 analogue adds two glucose-destabilizing anabolic signals and compounds soft-tissue/organ overgrowth risk, while LR3 simultaneously suppresses endogenous GH via negative feedback, making the combination both riskier and pharmacologically self-defeating.

    PMID 9488001 (LR3 reduced plasma GH by 23%, GH peak AUC by 60%, IGFBP-3 and endogenous IGF-I in pigs); PMID 9252489 (GH + Long-R3-IGF-I co-administration in neonatal calves; native IGF-I was highest with rbGH but was lowered by subcutaneous LR3)

  • Alcohol

    CautionModerate

    Alcohol suppresses hepatic gluconeogenesis and blunts hypoglycemia awareness, meaningfully amplifying the dominant acute risk of an IGF-1 analogue; the label already advises against high-risk activity for 2-3 hours after dosing for the same reason.

    Increlex FDA label, Warnings 5.1 (post-dose hypoglycemia window; label-sourced); established alcohol effect on hepatic gluconeogenesis. Mechanism-based - no LR3-alcohol study exists.

  • Non-selective beta-blockers

    CautionModerate

    Mask the adrenergic warning signs of hypoglycemia (tremor, palpitations, sweating), so a user can progress to neuroglycopenia without the usual prodrome - a well-established interaction pattern with insulin-like agents.

    Class interaction established for insulin and insulin-like hypoglycemic agents; applicability rests on the verified glucose-lowering action of the analogue (PMID 9483305) plus Increlex FDA label Warnings 5.1. No LR3-specific study.

  • Corticosteroids (glucocorticoids)

    CautionLow

    Glucocorticoids induce IGF-1 resistance and catabolic signaling in muscle and raise blood glucose, so they blunt the anabolic effect while confounding glycemic monitoring - a reduced-efficacy interaction rather than a safety one.

    Mechanism-based only; no LR3-specific interaction study identified. Retained at Low because the note itself is explicit that this is an efficacy rather than safety interaction.

  • Anabolic-androgenic steroids and other growth-promoting compounds

    CautionTheoretical

    This combination is undocumented in the peer-reviewed literature and layers cardiometabolic, proliferative and endocrine-suppressive risk with no safety data of any kind. The in vivo LR3 record does not support additive anabolism: LR3 alone reduced growth in pigs.

    No primary interaction study exists; PMID 9488001 shows LR3 monotherapy reduced growth in pigs, undercutting the assumed additive-hypertrophy premise.

Known risks(10)

  • Hypoglycemia (low blood sugar) - most common acute side effect, reported at virtually all dose levels; risk dramatically increased when combined with insulin, with fatalities reported

  • Potential cancer acceleration - promotes cell growth and inhibits apoptosis; one observational study linked higher endogenous IGF-1 to increased all-cancer mortality in older men; it did not measure LR3 risk

  • Insulin resistance with chronic use - frequent use can push the body toward insulin resistance, creating long-term metabolic complications

  • Fluid retention and edema - water retention is a commonly reported side effect

  • Joint pain and stiffness - musculoskeletal discomfort is frequently reported

  • Acromegaly-like changes with prolonged use - potential for bone and soft tissue overgrowth with long-term exposure

  • Endocrine disruption - suppression of natural growth hormone and IGF-1 production via negative feedback

  • No human clinical trial safety data - all safety information is extrapolated from animal studies and native IGF-1 human data

  • Unregulated product quality - unregulated products sold online are not made to pharmaceutical manufacturing standards (GMP); contamination and dosing inaccuracies are possible

  • Headaches and nausea - commonly reported at various dose levels

Drug interactions(5)

  • Insulin (exogenous)

    Critical - Life-threatening

    Severe and potentially fatal hypoglycemia. IGF-1 LR3 and insulin both lower blood glucose through different mechanisms; combined use dramatically amplifies hypoglycemia risk. Fatalities have been reported from this combination.

  • Sulfonylureas and other diabetes medications

    High

    Additive hypoglycemic effect. IGF-1 LR3 enhances glucose uptake; combining with glucose-lowering medications increases hypoglycemia risk.

  • Growth Hormone (GH/HGH)

    Moderate to High

    Synergistic growth factor activity. GH stimulates endogenous IGF-1 production; adding exogenous LR3 may cause supraphysiologic IGF-1R activation. May amplify both beneficial and adverse effects including fluid retention, insulin resistance, and cancer risk.

  • Corticosteroids

    Moderate

    Corticosteroids suppress IGF-1 signaling and can antagonize LR3 effects. Chronic corticosteroid use may blunt IGF-1 LR3 efficacy while both agents independently worsen glucose regulation.

  • Anticoagulants (Warfarin, Heparin)

    Low to Moderate (theoretical)

    IGF-1 may affect platelet function and vascular biology; potential for altered bleeding risk when combined with anticoagulants. Clinical significance in humans is not established for LR3.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
50
Human Studies
0

No human clinical trials have been conducted on IGF-1 LR3 specifically. All evidence comes from animal models (guinea pigs, sheep, mice) and in vitro cell culture studies. Human safety and efficacy data are extrapolated from native IGF-1 clinical studies (mecasermin/Increlex). The compound remains a research reagent without regulatory pathway for human therapeutic use.

Researched for(6)

Rated by confidence in the evidence

  • Enhanced muscle protein synthesis and hyperplasia

    Low

    Stimulates muscle cell proliferation in culture, but animal growth studies show no consistent benefit.

    PMID 15254966 (LongR3-IGF-I-stimulated L6 myoblast proliferation); PMID 15817840 (LongR3-IGF-I-stimulated porcine embryonic myoblast proliferation); PMID 9488001 (LR3 reduced growth in pigs - counterevidence)

  • Extended biological activity vs native IGF-1

    Medium

    Animal studies confirm reduced IGFBP binding and altered circulation, but no human pharmacokinetic data exists.

    PMID 7561636; PMID 9483305; PMID 9252489

  • Improved nutrient partitioning and glucose uptake

    Low

    Lowered glucose and insulin in calves, though the partitioning effect appears weaker than commonly claimed.

    PMID 9483305 (LR3 lowered plasma glucose and insulin in calves); PMID 11999215 (absorption effects less pronounced than mucosal growth); Increlex (mecasermin) FDA label - hypoglycemia as most common adverse reaction

  • Organ growth and tissue repair stimulation

    Low

    Animal studies show organ enlargement and gut growth, with no human data or wound-repair evidence.

    PMID 7561636; PMID 11999215

  • Cellular proliferation through dual signaling pathways

    Low

    Activates cell growth pathways in lab studies only, a mechanism also linked to cancer risk.

    PMID 23658701 (LR3-IGF-I, survivin/TGF-beta/mTORC1 axis, PLoS One 2013); PMID 15254966

  • Potential neuroprotective effects (early research)

    Speculative

    LR3 altered amyloid pathology in 5XFAD mice but did not preserve cognition; no human neuroprotective benefit is established.

    PMID 39610283: LR3-specific mouse study; amyloid changes without cognitive preservation.

Benefits(6)

  • Enhanced muscle protein synthesis and hyperplasia

    Animal and in vitro studies show IGF-1R activation via PI3K/Akt promotes protein synthesis and satellite cell activation, driving both muscle hypertrophy and hyperplasia (new fiber formation).

  • Extended biological activity vs native IGF-1

    Reduced IGFBP binding increases potency in some assays; a 20–72-hour human half-life is unestablished.

  • Improved nutrient partitioning and glucose uptake

    IGF-1R signaling enhances glucose and amino acid uptake in muscle cells, directing nutrients toward muscle repair rather than fat storage.

  • Organ growth and tissue repair stimulation

    Conlon et al. (1995) demonstrated LR3 IGF-I infusion significantly increased fractional weight of adrenals, gut, kidneys, and spleen in guinea pigs over 7 days.

  • Cellular proliferation through dual signaling pathways

    Sundgren et al. (2003) showed LR3 IGF-1 increased cardiomyocyte BrdU uptake 3-5 fold via both ERK and PI3K cascades, demonstrating potent mitogenic effects.

  • Potential neuroprotective effects (early research)

    Engel et al. (2025) showed intranasal LR3-IGF-1 promoted amyloid plaque remodeling and reduced filamentous plaques in 5XFAD Alzheimer's mice, though cognitive benefits were not observed.

Key studies(5)

  1. Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ

    Journal of Endocrinology

    1995

    LR3 IGF-I at 120 mcg/day significantly increased fractional weight of adrenals, gut, kidneys, and spleen. Plasma IGF-I, IGF-II, and IGFBP concentrations were reduced. Standard IGF-I/II infusions produced minimal systemic growth effects despite increased circulating levels.

  2. Sundgren NC, Giraud GD, Schultz JM, Lasarev MR, Stork PJS, Thornburg KL

    American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

    2003

    LR3 IGF-1 increased cardiomyocyte BrdU uptake (proliferation marker) by 3-5 fold. Both ERK and PI3K signaling pathways were required for proliferation. Blocking either pathway completely abolished growth factor-stimulated division. IGF-1 promoted hyperplastic rather than hypertrophic growth.

  3. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice

    Animal study (in vivo, transgenic mice)19-27 mice per group across wildtype and 5XFAD cohorts7 months (treatment from age 3-10 months)

    Engel MG et al.

    Journal of Alzheimer's Disease

    2025

    Intranasal LR3-IGF-1 reduced filamentous amyloid plaques and increased inert plaques in cortex. Decreased low molecular weight amyloid-beta oligomers and enhanced microglial uptake of amyloid-beta. However, failed to preserve cognitive function or memory across multiple behavioral assays.

  4. Bailes J, Soloviev M

    Biomolecules

    2021

    IGF-1 LR3 described as approximately 3x more potent than native IGF-1 with much lower IGFBP affinity. No internationally recognized test for detecting recombinant IGF-1 abuse exists. IGFBPs bind ~98% of circulating IGF-1, complicating measurement. Elevated circulating IGF-1 linked to 1.82-2.61 fold increased cancer mortality risk.

  5. MacDonald RS

    Hormone and Metabolic Research

    1999

    LR3-IGF-I is not only more potent than native IGF-1 but also induces proliferative events more rapidly in intestinal epithelium. Administration by osmotic pump affects the small intestine similarly to IGF-I but with higher potency.

What research suggests over time

  • Weeks 2-4

    Practitioner-reported

    Practitioner-reported recovery and growth signals only; no published human trial data.

  • Months 2-3

    Preclinical (mouse/sheep)

    Preclinical: increased fractional weight of gut, kidneys, adrenals, and spleen in animal models; cardiomyocyte proliferation 3-5×.

  • Long-term

    Preclinical only

    All evidence from animal models. No human clinical trials have ever been conducted on IGF-1 LR3 specifically. Bodybuilding use involves an unapproved substance.

Regulation & availability

Why researchers look at it

Engineered modifications reduce carrier binding and increase potency in some laboratory assays; human half-life is unestablished. No human clinical trial has ever been conducted — all safety and efficacy data is extrapolated from native IGF-1 studies. Recent research exploring intranasal delivery for Alzheimer's showed changes in amyloid plaques in animal models, which could open a therapeutic direction beyond performance use if human studies follow.

FDA status
IGF-1 LR3 is not FDA-approved and is not eligible for compounding in the US. Increlex contains native recombinant IGF-1, not LR3, and is approved for growth failure in pediatric patients aged two years and older with severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies to GH.
WADA status
PROHIBITED at all times under S2.3 of the 2026 WADA Prohibited List, effective January 1, 2026. IGF-1 analogues include LR3 and DES. WADA's general TUE process requires a documented medical indication and satisfaction of its criteria; an exemption for LR3 was not established. Mass-spectrometry detection methods have been published.
Prescribability
IGF-1 LR3 is not FDA-approved and is not eligible for compounding in the US.
Availability
IGF-1 LR3 is not FDA-approved and is not available by prescription in any standard medical formulary. Some clinics may list it, but a listing does not establish approval or eligibility for compounding. Increlex (mecasermin) is a different molecule, native IGF-1, approved for specified pediatric growth-failure conditions. No pharmaceutical-grade product exists for human use. Unregulated products sold online vary in quality. No insurance coverage exists for IGF-1 LR3.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(7)

  1. 1990s
    IGF-1 LR3 developed as a research reagent for cell culture and animal studies. 83-amino-acid analog with extended half-life and reduced IGFBP binding characterized.
  2. 2005
    Mecasermin (Increlex), containing native recombinant IGF-1 (not LR3), approved by FDA for severe primary IGF-1 deficiency (Laron syndrome) in children.
  3. 2005-2010
    IGF-1 products including analogs gain popularity in athletic doping, appearing in high-profile scandals (BALCO, MLB, Tour de France). WADA adds IGF-1 and analogs to Prohibited List.
  4. 2017
    Increased enforcement against misleading marketing of growth factor peptides.
  5. 2023-2024
    FDA increases scrutiny of compounding pharmacies selling peptides. Several peptides removed from compounding lists, though IGF-1 LR3 was never on compounding formularies.
  6. 2025
    Engel et al. publish research on intranasal LR3-IGF-1 for Alzheimer's disease in 5XFAD mice, representing one of the first studies exploring LR3 specifically for neurodegenerative conditions.
  7. 2026
    2026 WADA Prohibited List continues to ban IGF-1 and all analogs under S2 category.

Sources & FAQs

Research sources(9)

  1. PubMed/NCBI - Primary biomedical literature database
  2. PubMed Central (PMC) - Full-text archive of biomedical journal articles
  3. Wikipedia - IGF-1 LR3 article with referenced chemical and pharmacological data
  4. WADA (World Anti-Doping Agency) - Prohibited List and policy statements on IGF-1
  5. USADA (US Anti-Doping Agency) - IGF-1 regulatory information
  6. Journal of Endocrinology - Conlon et al. 1995 animal study
  7. American Journal of Physiology - Sundgren et al. 2003 cell proliferation study
  8. Journal of Alzheimer's Disease - Engel et al. 2025 intranasal LR3-IGF-1 study
  9. Biomolecules - Bailes & Soloviev 2021 review of IGF-1 monitoring

Frequently asked questions(6)

What is the difference between IGF-1 and IGF-1 LR3?

IGF-1 LR3 is a synthetic analog of natural IGF-1 with two key modifications: an arginine replacing glutamic acid at position 3, and 13 extra amino acids added to the N-terminus. These changes reduce carrier binding. Potency varies by assay; a 20–72-hour human half-life is unestablished.

Is IGF-1 LR3 legal?

It is not a controlled substance under DEA schedules. However, it is not approved for human consumption or medical treatment, and it is banned by WADA and all major sports organizations. Using it in competitive athletics can result in disqualification and sanctions.

Has IGF-1 LR3 been tested in humans?

No human clinical trials have been conducted on IGF-1 LR3 specifically. All research has been in animal models (mice, guinea pigs, sheep) and cell cultures. Human data is extrapolated from studies on native IGF-1 and the FDA-approved drug mecasermin (Increlex), which uses native IGF-1, not the LR3 variant.

What are the main risks of using IGF-1 LR3?

The most significant risks include hypoglycemia (low blood sugar, reported in ~50% of native IGF-1 clinical trial participants), potential acceleration of existing cancers due to IGF-1's role in promoting cell growth and inhibiting cell death, insulin resistance with chronic use, fluid retention, joint pain, and suppression of natural growth hormone production. Combining with insulin has caused fatalities.

Can IGF-1 LR3 cause cancer?

There is no direct evidence that IGF-1 LR3 causes cancer. However, because IGF-1 promotes cell growth and inhibits apoptosis (programmed cell death), it may accelerate the progression of existing or dormant tumors. An observational study linked higher endogenous IGF-1 to increased all-cancer mortality in older men; this does not quantify LR3 risk. Individuals with cancer history or strong genetic predisposition should avoid IGF-1 products.

How is IGF-1 LR3 typically administered?

IGF-1 LR3 is administered via subcutaneous or intramuscular injection. Using it with insulin adds to the risk of severe hypoglycemia.